Medullary Thyroid Carcinoma

Researchers are evaluating 177Lu-CTR-FAPI, a new radiopharmaceutical, for treating thyroid cancer in a multi-center, open-label phase I trial. The study aims to determine the safety, tolerability, and preliminary effectiveness of this treatment, focusing on dose-limiting toxicities to find the maximum tolerated dose. The research also assesses biochemical and radiological responses, quality of life improvements, and the dosimetry profile of 177Lu-CTR-FAPI. Participants will receive intravenous infusions of 177Lu-CTR-FAPI every 6 weeks for up to 4 cycles. The dosing starts at 100 mCi and increases by 50 mCi increments following a standard 33 dose-escalation design. Dose delays are allowed based on treatment response or recovery needs, with a maximum delay of 12 weeks after the previous dose. Vital signs and adverse reactions will be closely monitored during infusions. During the study, participants will undergo assessments including biochemical and radiological evaluations, quality of life and pain score measurements, and dosimetry scans to measure radiation absorbed by organs and tumors. The primary outcome focuses on safety and dose-limiting toxicities within 6 weeks after the first injection. Secondary outcomes include response rates, survival, and quality of life changes up to one year after the last treatment. Overall, the trial involves close monitoring and evaluation over several months to understand the treatments safety and impact.

Researchers are evaluating the safety and effectiveness of a new molecular probe called 18F-FAPI-YQ104, which targets fibroblast activation protein FAP, for early tumor diagnosis. This observational study focuses on patients with lung cancer, pancreatic cancer, neuroendocrine tumors, and thyroid cancer. The goal is to verify how well this probe works in detecting tumors during clinical use. Participants will receive an intravenous injection of the 18F-FAPI-YQ104 probe followed by a PET-CT examination to capture detailed images of tumor lesions. The study will observe the probes uptake in tumor sites, measured by SUVmax values 60 minutes after administration. No additional treatment is given instead, the study monitors the imaging results to assess the probes diagnostic potential. During the study, participants will undergo PET-CT scans and other imaging tests such as CT or MRI. Researchers will evaluate the images to measure tumor activity and probe uptake. Safety assessments include checking kidney and liver function, blood counts, and monitoring for allergic reactions. The study will last from April 2025 to March 2026 and includes adults aged 18 to 75 years who have confirmed tumors and meet health criteria.

This research aims to evaluate the use of a specialized imaging technique called 68Ga-labeled targeted covalent radiopharmaceutical TCR fibroblast activation protein inhibitor FAPI PETCT to guide surgery for medullary thyroid carcinoma MTC. Surgery is currently the only curative option for MTC, but existing imaging methods and calcitonin tests are not sufficient to fully map the disease. This study focuses on whether 68Ga-TCR-FAPI PETCT can better identify the extent of MTC and improve surgical planning. Participants are divided into three groups those newly diagnosed with MTC, those with recurrent or persistent MTC after prior treatment, and those with distant or unresectable lesions but still recommended for surgery. Surgery will be performed based on the lesion range revealed by the 68Ga-TCR-FAPI PETCT scan, aiming to remove all identified lesions when possible. The surgical principles follow current standards, including lymph node dissection when needed. During the study, researchers will measure calcitonin levels one month after surgery as the primary outcome. Secondary outcomes include two-year event-free survival, how often surgical plans change based on imaging results, and the accuracy of 68Ga-TCR-FAPI PETCT in detecting MTC lesions. Participants will undergo PETCT scans, surgery guided by imaging findings, and follow-up assessments to monitor outcomes and safety up to two years after surgery.

Researchers are evaluating the benefits and risks of prophylactic central lymph node dissection in patients with low-risk papillary thyroid carcinoma PTC, specifically in those with primary tumors classified as cT1b-T2N0. PTC is the most common thyroid cancer, usually treated with surgery, but the need for removing lymph nodes that do not show obvious cancer involvement remains unclear. This study aims to clarify whether routine removal of these lymph nodes improves treatment response, reduces recurrence, and helps guide decisions about radioactive iodine therapy, while considering the risk of complications. The study randomly assigns participants to one of two groups one group undergoes prophylactic central neck dissection on the side of the lesion, and the other group does not receive central neck dissection. Surgery is the primary intervention, and the trial is open-label and multicenter. The study includes adult patients aged 18 to 70 years with specific tumor sizes and no suspicious lymph nodes detected before surgery. Participants will be followed for at least one year to assess treatment response, measured by excellent response rates, and recurrence-free survival at one and two years. Assessments include monitoring thyroglobulin and its antibodies to evaluate short-term treatment outcomes. Study visits and follow-up tests will help track disease status and safety. The total participation duration is expected to cover these time points, supporting evaluation of long-term benefits and risks of the surgical approach.

Researchers are evaluating AL2846, a multi-target tyrosine kinase inhibitor, in adults with locally advanced or metastatic differentiated thyroid cancer that no longer responds to iodine treatment and has progressed after previous VEGFR-targeted therapies. This Phase III trial aims to see if AL2846 can extend the time patients live without their cancer worsening compared with a placebo. The study is led by Chia Tai Tianqing Pharmaceutical Group and involves random assignment to treatment groups with both patients and investigators unaware of the assignments. Participants will receive either AL2846 capsules or a placebo in 28-day treatment cycles. The AL2846 drug targets specific receptors involved in tumor growth, including c-MET, c-KIT, VEGFR1, and RET. The study will last up to 34 months, during which patients will be monitored for disease progression, response rates, survival, and safety. Both groups follow the same cycle length to compare outcomes fairly. Throughout the trial, participants will undergo regular assessments including imaging scans to measure tumor size, blood tests to monitor health status and safety, and evaluations by an independent review committee and researchers. Researchers will track progression-free survival as the main outcome, along with overall survival, response rates, and duration of response. Safety of AL2846 compared to placebo will also be closely monitored. Participants involvement may last up to nearly three years, allowing for detailed observation of treatment effects and tolerability.

Researchers are evaluating the combination of avutometinib and defactinib as a treatment for patients with RAF dimer-driven radioiodine-refractory differentiated thyroid cancer or anaplastic thyroid cancer. This phase II study aims to assess whether this combination is effective and safe, causing few or mild side effects. The trial is sponsored by Memorial Sloan Kettering Cancer Center and funded by the FDA Office of Orphan Products Development. Participants receive avutometinib at 3.2 mg twice weekly and defactinib at 200 mg twice daily, both given in cycles of 3 weeks on treatment followed by 1 week off. There are two patient groups one with radioiodine-refractory, recurrent or metastatic differentiated thyroid cancer, and the other with anaplastic thyroid cancer. Both groups are treated similarly with this drug combination throughout the study period. During the study, participants undergo assessments to measure tumor response using the overall response rate over up to two years. They will have biopsies and provide tumor tissue for correlative studies. Safety and side effects are monitored, including heart function tests and laboratory evaluations. The total study duration for each participant can last up to two years, with regular visits for treatment and evaluation.

This research aims to evaluate whether Meaning-Centered Psychotherapy for Latinos MCP-L helps reduce anxiety and depression and improves quality of life compared to cognitive behavioral therapy CBT in Mexican adults with advanced cancer. The study also explores participants and providers perspectives on the therapy design, external factors, available resources, and the influence of involved individuals on MCP-Ls effectiveness. Participants will be randomly assigned to receive either MCP-L or CBT. MCP-L is a culturally adapted, manualized therapy consisting of seven 60-minute individual sessions delivered weekly or intermittently over about three months, focusing on themes related to meaning and advanced cancer. CBT serves as the comparison group to assess differences in outcomes. Throughout the study, participants will undergo assessments of anxiety and depression levels at one and three months to measure changes. Researchers will collect feedback on therapy experiences and monitor participants mental health status, including suicide risk assessments. The study is led by Memorial Sloan Kettering Cancer Center and aims to support adults aged 18 and older with advanced cancer.

Researchers are collecting information on the use of redifferentiating medications as a standard treatment for patients with radioactive iodine RAI-refractory thyroid cancer. This study is a registry designed to learn more about how these medications are used in routine clinical care for this condition. It is an observational study focused on patients who have thyroid cancer that does not respond well to RAI treatment. Participants will undergo follow-up visits at intervals determined by their usual clinical care. During these visits, researchers will record how well patients tolerate the redifferentiating medications and any adverse events they experience. The study includes patients receiving these agents as part of their regular treatment, both prospectively and retrospectively, but excludes those receiving such agents within other clinical trials. Participants will be monitored for adverse events at every visit over a period of two years. Researchers will collect and review data on medication tolerance and side effects during these follow-up appointments. This ongoing observation aims to provide a clearer picture of outcomes for patients treated with redifferentiation agents in usual care settings.

Researchers are evaluating the safety and effects of PF-07799544 alone or combined with PF-07799933 as a potential treatment for adults with advanced solid tumors that have a BRAF V600 mutation. This phase 1ab open-label study is focused on patients with metastatic or recurrent solid tumors, excluding colorectal cancer. The trial includes two parts phase 1a studying PF-07799544 alone and phase 1b studying the combination of both drugs. Phase 1a enrollment is closed, while phase 1b is actively seeking participants. In this study, all participants receive both PF-07799544 and PF-07799933 as oral tablets taken at home twice daily. Treatment continues until cancer progression, unacceptable side effects, or a maximum of two years, with the option to extend therapy beyond two years. The study aims to understand patient experiences with these medicines and to determine their safety and effects. Participants will undergo regular assessments including monitoring for dose-limiting toxicities, adverse events, lab abnormalities, vital signs, and physical exams from baseline through the treatment period and up to 28 days after the last dose. The primary outcome evaluates overall response rate during the two-year treatment. Additional pharmacokinetic data and long-term safety are also collected. The total participation duration may extend up to two years or longer if treatment continues.

Researchers are evaluating the safety and effects of a study medicine called PF-07799933 in people aged 16 years and older who have advanced solid tumors with specific BRAF gene alterations. The study focuses on participants whose cancers have progressed after prior treatments and for whom no satisfactory alternative options remain. The trial is a phase 1, open-label study aiming to assess PF-07799933 alone and in combination with other study medicines. Participants will receive PF-07799933 tablets twice daily. Depending on the study part and tumor type, participants may also receive binimetinib tablets twice daily, or cetuximab injections weekly or every two weeks. Some participants with colorectal cancer may additionally receive a chemotherapy regimen called mFOLFOX6. Treatment duration may last about two years, with close monitoring during regular clinic visits. Throughout the study, participants will have their safety evaluated by tracking dose-limiting toxicities, adverse events, laboratory and vital sign changes, and physical exams. Researchers will also monitor treatment responses and pharmacokinetics of PF-07799933. Dose adjustments or interruptions may occur due to side effects. The study includes ongoing assessments during and up to 28 days after treatment, with overall participation lasting up to two years or more.